Acasti Pharma Inc. Class A Stock

$3.45

11.13%

Nasdaq, Jul 11, 10:08 pm CET

ISIN

CA00430K4028

Symbol

GRCE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Acasti Pharma Inc. Class A Stock price

$3.45

-30.00 89.70% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

+0.35 11.13%

ISIN

CA00430K4028

Symbol

GRCE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$47.6m

Enterprise Value

$25.5m

Net debt

positive

Cash

$22.1m

Shares outstanding

13.7m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

0.7

Financial Health

Equity Ratio

92.5%

Return on Equity

ROCE

-23.8%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-16.7m | $-17.9m

EBIT

$-16.7m | $-17.2m

Net Income

$-9.6m | $-11.6m

Free Cash Flow

$-14.9m

EPS

$-0.7

FCF per Share

$-1.1

Short interest

0.5%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Acasti Pharma Inc. Class A Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Acasti Pharma Inc. Class A forecast:

8x Buy

89%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Acasti Pharma Inc. Class A forecast:

Buy

89%

Hold

11%

Analyst Estimates with Stock Price Targets

Financial data from Acasti Pharma Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	7.16 7.16	8% 8% -
- Research and Development Expense	3.25 3.25	550% 550% -
EBITDA	-17 -17	48% 48% -
- Depreciation and Amortization	0.01 0.01	83% 83% -
EBIT (Operating Income) EBIT	-17 -17	47% 47% -
Net Profit	-9.57 -9.57	26% 26% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Acasti Pharma Inc. Class A Stock News

Neutral

GlobeNewsWire

●

19 days ago

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 Submission Has the Potential to Trigger Exercise of up to $7.6 million in Gross Proceeds from 2023 Financing Warrants Tied to FDA Acceptance of NDA for Review PRINCETON, N.J., June 25,...

Neutral

GlobeNewsWire

●

21 days ago

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First Half of Calendar 2025 NDA to be Supported by Data from Phase 3 STRIVE-ON Safety Trial, which Met Primary Endpoint and Provided Evidence of Clinical Benefit Compared to Orally Admi...

Neutral

GlobeNewsWire

●

about one month ago

Grace Therapeutics to Participate in the 2025 BIO International Conference

PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief...

More Acasti Pharma Inc. Class A News

Company Profile

Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.

Head office	Canada
CEO	Mr. Kohli
Founded	2002
Website	www.gracetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now